This histogram enumerates side effects from a completed 2020 Phase 3 trial (NCT04152083) in the Eptinezumab ARM group. Side effects include: Hypersensitivity with 2%.
Trial Design
3 Treatment Groups
Eptinezumab 300 mg
1 of 3
Eptinezumab 100 mg
1 of 3
Placebo
1 of 3
Experimental Treatment
Non-Treatment Group
285 Total Participants · 3 Treatment Groups
Primary Treatment: Eptinezumab · Has Placebo Group · Phase 3
Eptinezumab 300 mg
Drug
Experimental Group · 1 Intervention: Eptinezumab · Intervention Types: Drug
Eptinezumab 100 mg
Drug
Experimental Group · 1 Intervention: Eptinezumab · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Eptinezumab
FDA approved
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: randomization ( pre-dose [week 0]), week 8, week 12, and safety follow up visit (week 20)
Who is running the clinical trial?
H. Lundbeck A/SLead Sponsor
317 Previous Clinical Trials
76,326 Total Patients Enrolled
Email contact via H. Lundbeck A/SStudy DirectorH. Lundbeck A/S
184 Previous Clinical Trials
57,662 Total Patients Enrolled
Eligibility Criteria
Age 12 - 17 · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:
The participant must complete the headache eDiary on at least 24 of the 28 days following the screening visit.
The participant must have at least 15 headache days, including at least 8 migraine days, during the 28-day screening period.
The participant has a history of migraine headaches lasting at least 6 months.